Therefore, L-APP detected by proseqff178928 could be used as a blood biomarker for Alzheimer's disease and as a biomarker for therapeutic efficacy since it is derived from astrocytes as well as GFAP and is detected more frequently in SAD than in NCI. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.